Recoverable intracranial drug eluting stent

Abstract

The utility model discloses a recyclable intracranial drug eluting stent. The recyclable intracranial drug eluting stent comprises a stent body (100) and a recyclable connecting claw (103), the support body (100) comprises a first subsection (101) and a second subsection (102). The whole stent body (100) is of a hollowed-out net cylinder structure, one end of the first section (101) is a conical opening, and the diameter reducing position of the other end of the first section (101) is fixedly connected with the second section (102) of the hollowed-out net cylinder structure. The first subsection (101) and the second subsection (102) are formed by hollow cosine wave unit grids which are connected with each other; and the recoverable connecting claw (103) is connected with the near end of the second section (102). According to the utility model, the problem that the existing aneurysm auxiliary stent cannot be safely recycled for multiple times after being partially released under the condition of ensuring the adherence and bending resistance can be solved.

Description

Technical Field

[0001] The utility model relates to a medical device manufacturing technology, in particular to a recyclable intracranial drug eluting stent. Background Art

[0002] Intracranial aneurysm is an abnormal protrusion formed by gradual expansion due to local damage to the blood vessel wall caused by congenital abnormalities or acquired injuries of the intracranial arteries and under the influence of hemodynamic load and related factors.

[0003] Intracranial aneurysms usually occur near the bifurcation of a blood vessel segment, and are most common in people aged 35 to 60. The bulging part of the aneurysm can compress nerves or brain tissue, and clinical symptoms include fatigue, peripheral vision impairment, thinking disorders, speech complications, loss of balance and coordination, etc. The most common serious sequelae of intracranial aneurysms are aneurysm rupture and subsequent subarachnoid hemorrhage (SAH).

[0004] According to relevant statistics in 2019, the mortality rate of intracranial aneurysms is about 50%, and the possibility of causing neurological diseases is 30% to 50%. In clinical diagnosis and treatment, it is generally believed that the main causes of intracranial aneurysms are abnormal degenerative vascular lesions and the compression caused by the blood flowing through the aneurysm and pumping forward.

[0005] Due to the tortuous and complex anatomical morphology of cerebral blood vessels, they have more and smaller bends than coronary arteries and peripheral blood vessels. For example, the bending angle of the blood vessels in the cavernous sinus segment of the internal carotid artery is 20° to 90°, and the bending radius ranges from 2mm to 4.5mm. Therefore, they have sufficient compliance for the vascular stents required to treat aneurysms.

[0006] At present, the main vascular stents for treating aneurysms are dense mesh stents and / There are two types of stents: aneurysm stents and aneurysm auxiliary stents. After dense mesh stents are implanted into blood vessels in the body, the stenosis rate is high in the later stage; dense mesh stents are expensive; and aneurysm auxiliary stents need to be used with spring coils.

[0007] Existing aneurysm auxiliary stents are mainly of two types: open-loop structure and closed-loop structure. Among them, the main advantages of the open-loop structure stent are good wall adhesion and bending resistance, and the stent is not easy to shift. However, the open-loop structure stent cannot be recovered after partial release, and the final placement of the stent cannot be guaranteed to be completely accurate; while the main advantage of the closed-loop structure stent is that the stent can be recovered 1 to 2 times after partial release, but it does not have the function of being able to be recovered more times after partial release, and the wall adhesion and bending resistance of the closed-loop structure stent are relatively poor. When the closed-loop structure stent collapses, folds, or is not completely adhered to the wall in the blood vessel, it is easy to cause thrombosis after surgery, and even lead to vascular occlusion. For example, in the invention application with application number CN202110182867.3 and titled “A novel intracranial stent system”, the intracranial stent disclosed therein is composed of a main wave rod including a sinusoidal wave structure and a secondary wave rod connected to the apex of the sinusoidal wave of the main wave rod, which are connected to each other to form a mesh closed-loop unit structure. The intracranial stent is an open-loop structure with a dense mesh structure, has good wall adhesion and flexibility, and also supports limited recycling of the stent after release. It adopts a smaller mesh design, which improves the supporting force to a certain extent, but it is still difficult to overcome the inherent shortcomings of the dense mesh structure stent. Utility Model Content

[0008] In view of this, the main purpose of the utility model is to provide a recyclable intracranial drug-eluting stent to solve the problem that the existing aneurysm auxiliary stent cannot achieve multiple safe recovery after partial release under the condition of ensuring wall adhesion and anti-bending properties. In addition,

[0009] In order to achieve the above object, the technical solution of the utility model is as follows:

[0010] A recyclable intracranial drug eluting stent comprises a stent body and a recyclable connecting claw; the stent body comprises a first segment and a second segment; the stent body as a whole is a hollow mesh tube structure, one end of the first segment is a conical opening, and the other end is fixedly connected to the second segment of the hollow mesh tube structure at a reduced diameter; the first segment and the second segment are composed of hollow and mutually connected cosine wave unit grids; the recyclable connecting claw is connected to the proximal end of the second segment.

[0011] Wherein: a plurality of main support rods are arranged along the axial direction of the bracket body, and each of the main support rods is a cosine waveform structure.

[0012] An auxiliary support rod is further provided between two adjacent main support rods of the bracket body, and two ends of each auxiliary support rod are respectively and staggeredly connected with two adjacent main support rods.

[0013] One end of the auxiliary support rod is connected to the trough of the cosine wave structure of the main support rod, and the other end is connected to the peak of the cosine wave structure of the adjacent main support rod; the outer diameter of the bracket body forms a group of auxiliary support rods along the axial direction; the two axially adjacent groups of auxiliary support rods are distributed in an "eight" shape or in parallel.

[0014] The rod width of the auxiliary support rod is smaller than the rod width of the main support rod.

[0015] The main support rod corresponds to the first segment and the second segment of the bracket body, and is divided into the first segment and the second segment; the first segment is composed of at least one cosine wavelength unit; the second segment is composed of multiple cosine wavelength units; the cosine structure meshes of the first segment and the second segment are smoothly transitioned and connected; the wavelength of the cosine wave unit of the first segment is greater than the wavelength of the cosine wave unit of the second segment; each cosine wavelength in the second segment is the same; the radial supporting force of the trumpet structure of the first segment is greater than the radial supporting force of the cylindrical hollow structure of the second segment.

[0016] The inner and outer surfaces of the stent body are processed to form a surface with a certain roughness, and the rough surface is provided with a drug coating for resisting acute thrombosis.

[0017] Preferably, a developing mark belt is wound along the main support rod of the bracket body, and at least one developing point is provided on the developing mark belt; the developing mark belt is fixed to the developing mark fixing rod of the first segment and / or the second segment by welding to form a developing point; the number of developing mark belts arranged on each of the bracket bodies is at least 2, and the number of each developing mark belt is consistent with the number of developing mark fixing rods.

[0018] The clamping portion of the recyclable connecting claw can be detachably connected through the recovery groove of the recyclable connecting piece of the conveying device.

[0019] The recyclable intracranial drug eluting stent of the utility model has the following beneficial effects:

[0020] The recyclable intracranial drug-eluting stent provided by the utility model has a first section of a stent body arranged in a trumpet shape, which enables the stent to have a strong radial supporting force after being released, thereby preventing the stent from shifting; its recyclable connecting claws enable the stent to have the function of being recyclable multiple times after partial release, so that the operator can repeatedly release and recycle the stent when placing the stent, thereby ensuring the accuracy of the final placement position of the stent.

[0021] The main support rod of the stent adopts a large mesh and cosine wave cell structure design, which can make the stent have better wall adhesion and bending resistance. At the same time, because the rod width of the main support rod is greater than the rod width of the auxiliary support rod, it ensures that it has wall adhesion and bending resistance while having strong anti-extrusion performance and supporting force. When used in conjunction with the trumpet-shaped first segment of the stent body, the stent can ensure a strong radial supporting force after release and avoid displacement of the stent. Furthermore, the drug coating on the surface of the stent can greatly reduce the occurrence of acute thrombosis after vascular stent interventional surgery. Therefore, the recyclable intracranial drug eluting stent of the utility model also has a structural design that is not easy to be displaced, which can prevent the spring coil from protruding from the aneurysm and reduce the occurrence of thrombosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is a schematic structural diagram of a recyclable intracranial drug-eluting stent according to Embodiment 1 of the utility model;

[0023] Figure 2a This is a schematic diagram of the deployment structure of a recoverable intracranial drug-eluting stent according to an embodiment of the utility model;

[0024] Figure 2b This is a schematic diagram of the deployment structure of a recyclable intracranial drug-eluting stent according to another embodiment of the utility model;

[0025] Figure 3a The structure of the recyclable connecting claw of the conveying device in one embodiment of the utility model is shown in FIG. Figure 1 ;

[0026] Figure 3b A second structural schematic diagram of a recyclable connecting claw of a conveying device in another embodiment of the utility model;

[0027] Figure 4 It is a schematic diagram of the development mark of a recyclable intracranial drug eluting stent in one embodiment of the utility model;

[0028] Figure 4a For this utility model Figure 4 The first developing point 1051 and the developing mark fixing rod 104 and the developing mark belt 105 are partially enlarged schematic diagrams shown;

[0029] Figure 4b For this utility model Figure 4 The second developing point 1052 and the developing mark fixing rod 104 and the developing mark belt 105 are partially enlarged schematic diagrams shown;

[0030] Figure 5 It is a schematic structural diagram of a delivery device for a recoverable intracranial drug-eluting stent in one embodiment of the utility model;

[0031] Figure 6 It is a schematic diagram of a recyclable connector of a delivery device for a recyclable intracranial drug-eluting stent in one embodiment of the utility model;

[0032] Figure 7 This is a schematic diagram of stent loading of a recyclable intracranial drug-eluting stent in one embodiment of the utility model;

[0033] Figure 8 Schematic diagram of a retrievable intracranial drug eluting stent in one embodiment of the utility model combined with a coil for treating an aneurysm Figure 1 , the figure shows a retrievable intracranial drug-eluting stent in a retrievable state;

[0034] Fig. 9 This is a second schematic diagram of a recoverable intracranial drug eluting stent in an embodiment of the present invention used in combination with a spring coil to treat an aneurysm, and the figure shows the recoverable intracranial drug eluting stent in a released state.

[0035]

Main parts / assembly symbols

[0036] 100: support body; 101: first segment; 102: second segment;

[0037] 103: recyclable connecting claw; 1031: connecting rod; 1032: clamping part;

[0038] 104: a developing mark fixing rod;

[0039] 105: development mark belt; 1051: first development point; 1052: second development point;

[0040] 201: main support rod; 2011: first section; 2012: second section;

[0041] 2013: (main support rod) trough; 2014: (main support rod) peak;

[0042] 202: auxiliary support rod;

[0043] 300: delivery device; 301: delivery guide wire; 302: recyclable connector;

[0044] 3021: Recycling groove;

[0045] 400: introduction sheath; 500: microcatheter; 600: aneurysm; 700: coil;

[0046] 800: Blood vessels. DETAILED DESCRIPTION

[0047] The scheme of the utility model is further described in detail below in conjunction with the accompanying drawings and embodiments of the utility model.

[0048] In order to more clearly illustrate and describe the embodiments of the utility model, one or more drawings are required to be referred to, but the additional details or examples used to describe the drawings are not intended to limit the scope of the utility model creation of the present application, the embodiments currently described, or any of the preferred modes. Unless otherwise defined, all technical terms or scientific terms used in the specification of the utility model have the same meaning as those commonly understood by technicians in the technical field of the utility model. The terms used in the specification of the utility model are only used to describe specific embodiments, not to limit the utility model.

[0049] In addition, the terms “distal end” and “proximal end” used in the present invention should be understood as being viewed from the direction of the operator, with the “distal end” being the side away from the operator and the “proximal end” being the side close to the operator.

[0050] Figure 1 This is a schematic structural diagram of a recoverable intracranial drug-eluting stent according to Embodiment 1 of the utility model.

[0051] like Figure 1 As shown, the recoverable intracranial drug eluting stent is in a hollow mesh structure in the released state, and mainly includes: a stent body 100 and a recoverable connecting claw 103. Among them:

[0052] The stent body 100 further comprises a first segment 101 and a second segment 102. The stent body 100 is a hollow net tube structure, wherein the first segment 101 has a conical opening at one end (distal end), i.e., a trumpet-shaped with a larger diameter; and is fixedly connected to the second segment 102 of the hollow net tube structure at the reduced diameter portion of the other end.

[0053] The first segment 101 and the second segment 102 are composed of a plurality of hollowed-out cosine wave unit grids connected to each other. The first segment 101 and the second segment 102 are connected with each other in a smooth transition.

[0054] The radial supporting force of the trumpet-shaped structure of the first segment 101 is greater than the radial supporting force of the cylindrical hollow structure of the second segment 102 , thereby preventing the stent body 100 from shifting after being released.

[0055] Preferably, the inner and outer surfaces of the stent body 100 are both provided with a drug coating, and the drug coating has an effect of resisting acute thrombosis, and the effect of the acute thrombosis can last for 3 to 7 days. The drug ingredients include anti-thrombotic and anti-platelet drugs such as aspirin, ozagrel, clopidogrel, cilostazol, dipyridamole, tirofiban, eptifibatide, low molecular weight heparin, heparin sodium, ligustrazine, etc.

[0056] In order to ensure that the drug loading on the inner and outer surfaces of the stent body 100 can be stably and continuously released, and also to increase the drug adhesion, the inner and outer surfaces of the stent body 100 can be processed to form a surface with a certain roughness, such as a surface roughness ranging from 0.012μm to 0.4μm. Preferably, the surface roughness reaches 0.05μm. The drug coating is applied to the inner and outer surfaces of the stent body 100 by immersion or spraying.

[0057] Figure 2a This is a schematic diagram of the deployment structure of a recoverable intracranial drug-eluting stent according to an embodiment of the utility model; Figure 2b This is a schematic diagram of the deployment structure of a recoverable intracranial drug-eluting stent according to another embodiment of the utility model.

[0058] like Figure 2a As shown, a plurality of main support rods 201 may be provided along the axial outer diameter of the support body 100, and each main support rod 201 is a cosine wave structure. The main support rod 201 is essentially one edge of a plurality of hollow, mutually connected cosine wave cells (grids) on the first segment 101 and the second segment 102 of the support body 100. The number of the main support rods 201 is at least 4.

[0059] The main support rod 201 is further divided into a first section 2011 and a second section 2012. The first section 2011 is composed of at least one cosine wavelength unit. Preferably, it contains one wavelength unit. The second section 2012 is composed of multiple cosine wavelength units. The first section 2011 and the second section 2012 are smoothly connected. The wavelength of the cosine wave structure of the first section 2011 is greater than the wavelength of the cosine wave structure of the second section 2012. The wavelengths of the multiple cosine wavelength units in the second section 2012 are the same.

[0060] The cosine wave structure of the first section 2011 is disposed on the first segment 101 of the bracket body 100 ; and the second section 2012 is disposed on the second segment 102 of the bracket body 100 .

[0061] refer to Figure 2a and Figure 2bAn auxiliary support rod 202 is also provided along the outer diameter of the support body 100, i.e., the circumferential direction. The two ends of the auxiliary support rod 202 are respectively connected to two adjacent main support rods 201 in an alternating manner, i.e., one end of the auxiliary support rod 202 is connected to the trough portion 2013 of the cosine wave structure of the main support rod 201, and the other end is connected to the peak portion 2014 of the cosine wave structure of the adjacent main support rod 201 (refer to Figure 2a Thus, a group of auxiliary support rods 202 are formed along the axial direction on the outer diameter of the stent body 100; two groups of auxiliary support rods 202 adjacent to each other in the axial direction are arranged in an "eight" shape or in parallel (refer to Figure 2b ).

[0062] Wherein: the width of the auxiliary support rod 202 is smaller than the width of the main support rod 201.

[0063] The first segment 101 and the second segment 102 of the support body 100 are respectively provided with a developing mark fixing rod 104 (refer to Figure 2a ). The developing mark fixing rod 104 is in the shape of a long strip. The number of developing mark fixing rods 104 provided on the first segment 101 is at least 2. Preferably, the number is set to 3. The number of developing mark fixing rods 104 provided on the second segment 102 is at least 2. Preferably, the number is set to 3.

[0064] Figure 3a The structure of the recyclable connecting claw of the conveying device in one embodiment of the utility model is shown in FIG. Figure 1 ; Figure 3b This is a second structural schematic diagram of the recyclable connecting claw of the conveying device in another embodiment of the utility model.

[0065] like Figure 3a , Figure 3b As shown, they are respectively with the conveying device 300 (detachable, refer to Figure 5 ) are two different structural schematic diagrams of the recyclable connecting claw 103 connected.

[0066] The stent body 100 is provided with at least one recyclable connection claw 103 , and the recyclable connection claw 103 is used for detachably connecting and retrieving the stent body 100 through a conveying device when the stent body 100 is not completely released.

[0067] The recyclable connecting claw 103 is disposed at one end (outer end) of the second segment 102 of the stent body 100. The stent body 100 is detachably connected to the conveying device via the recyclable connecting claw 103.

[0068] like Figure 3a and Figure 3bAs shown, the recyclable connecting claw 103 further includes a connecting rod 1031 and a clamping portion 1032 disposed at the distal end of the connecting rod 1031. The clamping portion 1032 can be configured as a spherical shape (refer to Figure 3a ) or clubbed (reference Figure 3b The recyclable connecting claw 103 is detachably connected to the conveying device via the clamping portion 1032 .

[0069] Figure 4 It is a schematic diagram of the development mark of a recyclable intracranial drug eluting stent in one embodiment of the utility model; Figure 4a For this utility model Figure 4 The first developing point 1051 and the developing mark fixing rod 104 and the developing mark belt 105 are partially enlarged schematic diagrams shown; Figure 4b For this utility model Figure 4 The second developing point 1052, the developing mark fixing rod 104 and the developing mark belt 105 are partially enlarged schematic diagrams shown.

[0070] In this embodiment, a developing mark tape 105 is wound around the support body 100, and one or more developing points are arranged on the developing mark tape 105. Figure 4 As shown, the support body 100 is provided with two developing mark bands 105, and the developing mark bands 105 are first fixed to the developing mark fixing rod 104 of the second segment 102 by welding to form a first developing point 1051 (refer to Figure 4a ), and then spirally wound along the main support rod 201 and fixed on the developing mark fixing rod 104 of the first segment 101 to form a second developing point 1052 (reference Figure 4b ). The number of the developing mark belts 105 provided on each of the bracket bodies 100 is at least 2, and the number of each developing mark belt 105 is consistent with the number of the developing mark fixing rods 104 .

[0071] Furthermore, the developing mark 105 of the bracket body 100 and the recyclable connecting claw 103 are alternately arranged along the outer diameter axial direction of the bracket body 100 , and the distance between the two is at least one main support rod 201.

[0072] Figure 5 It is a schematic structural diagram of a delivery device for a recoverable intracranial drug-eluting stent in one embodiment of the utility model; Figure 6 This is a schematic diagram of a recyclable connector of a delivery device for a recyclable intracranial drug-eluting stent in one embodiment of the utility model.

[0073] like Figure 5The delivery device 300 shown in the figure is provided with the delivery guide wire 301 and the recyclable connecting member 302. The recyclable connecting member 302 is further provided with a recycling groove 3021. The inner diameter of the recycling groove 3021 is larger than the outer diameter of the clamping portion 1032 of the recyclable connecting claw 103 (refer to Figure 6 ).

[0074] Figure 7 The figure is a schematic diagram of stent loading of a retrievable intracranial drug-eluting stent in one embodiment of the utility model.

[0075] exist Figure 7 In one embodiment shown, the stent body 100 is loaded into the introduction sheath 400 after being compressed, and the clamping portion 1032 of the recyclable connecting claw 103 of the stent body 100 is movably connected to the recovery groove 3021 of the recyclable connecting member 302 of the conveying device 300.

[0076] Furthermore, during the vascular stent implantation surgery, the axial length of the contracted stent will change (elongate or shorten) during the release process, that is, the distal end of the stent body 100 will change during the release process, making it difficult for the operator to accurately release the stent at the predetermined target position in one operation. Therefore, after partially releasing the stent, it is necessary to recover the stent multiple times to continuously adjust the release position of the stent so that it can be accurately released at the target position.

[0077] The utility model also provides a method for manufacturing a recyclable intracranial drug-eluting stent, which comprises at least the following steps:

[0078] First, a metal tube is cut to produce a bracket body (100); specifically, the metal tube is extruded and processed into a trumpet-shaped opening at one end and a mesh tube structure as a whole, and then the metal tube is cut and divided into a first segment (101) with a conical opening at one end and a second segment (102) with a reduced diameter and the hollow mesh tube structure to form a bracket body (100); the first segment (101) and the second segment (102) are connected to each other by a hollow and mutually connected cosine wave unit grid; and the proximal end of the second segment (103) is processed to form a recyclable connecting claw (103).

[0079] Secondly, the stent body 100 can be further processed, such as roughening its inner and outer surfaces, so as to form a drug coating on its inner and outer surfaces by immersion or spraying. The drug coating has the effect of preventing acute thrombosis.

[0080] The specific operation process of using the recyclable intracranial drug-eluting stent of the utility model to treat aneurysm surgery is described in detail below.

[0081] Figure 8 Schematic diagram of a retrievable intracranial drug eluting stent in one embodiment of the utility model combined with a coil for treating an aneurysm Figure 1 , the figure shows a retrievable intracranial drug-eluting stent in a retrievable state; Fig. 9 This is a second schematic diagram of a recoverable intracranial drug eluting stent in an embodiment of the present invention used in combination with a spring coil to treat an aneurysm, and the figure shows the recoverable intracranial drug eluting stent in a released state.

[0082] First, the location of the aneurysm 600 is confirmed by angiography, and then the coil 700 is implanted into the lesion position of the human blood vessel 800 by interventional surgery to block the aneurysm 600. Figure 8 shown.

[0083] In order to further prevent the coil 700 from protruding from the inside of the aneurysm 600 into the blood vessel 800, the retrievable intracranial drug eluting stent is implanted into the aneurysm 600 through interventional surgery. When the release position of the retrievable intracranial drug eluting stent is deviated, and the retrievable intracranial drug eluting stent is not completely released from the microcatheter 500, the retrievable intracranial drug eluting stent is still in the microcatheter 500 as can be seen by angiography. At this time, the retrievable connecting claw 103 of the stent body 100 is still connected to the retrievable connecting piece 302 of the delivery device 300, as shown in FIG. Figure 8 As shown in . The retrievable intracranial drug eluting stent can be retrievable multiple times and then released again to adjust the retrievable intracranial drug eluting stent to an accurate release position.

[0084] When the release position of the retrievable intracranial drug eluting stent corresponds to the position of the aneurysm 600, the retrievable intracranial drug eluting stent continues to be released. When the retrievable connecting claws 103 are all released from the microcatheter 500, the retrievable connecting claws 103 can be immediately disconnected from the retrieving groove 3021 of the retrievable connecting member 302. At this time, the retrievable intracranial drug eluting stent is released completely. Fig. 9 shown.

[0085] It should be further explained that, in a curved blood vessel 800, when the stent body 100 fits against the inner recess of the blood vessel 800, the main support rod 201 is subjected to an extrusion force, and the second section 2012 of the main support rod 201 is extruded and deformed. Since the main support rod 201 of the stent body 100 is a cosine wave structure, it can ensure that the stent body 100 has both good wall adhesion and good bending resistance, thereby ensuring that the stent body 100 conforms to the blood vessel 800 and has a good wall adhesion effect.

[0086] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installation", "connection" and "connection" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0087] The terms "first", "second", "third", and "fourth" mentioned in the present invention are used for descriptive purposes only and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first", "second", "third", and "fourth" may explicitly or implicitly include one or more of the features.

[0088] Although the present invention has been described with reference to preferred embodiments, various modifications may be made thereto and parts thereof may be replaced with equivalents without departing from the scope of the present invention. In particular, the various technical features mentioned in the various embodiments may be combined in any manner as long as there is no structural conflict. The present invention is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.

[0089] The above description is only a preferred embodiment of the present invention and is not intended to limit the protection scope of the present invention.

Claims

1. A recyclable intracranial drug-eluting stent, characterized in that: The invention comprises a support body (100) and a recyclable connecting claw (103); the support body (100) comprises a first segment (101) and a second segment (102); the support body (100) is in the form of a hollow mesh tube structure as a whole, one end of the first segment (101) is a conical opening, and the other end is fixedly connected to the second segment (102) of the hollow mesh tube structure at a reduced diameter; the first segment (101) and the second segment (102) are composed of hollow and mutually connected cosine wave unit grids; the recyclable connecting claw (103) is connected to the proximal end of the second segment (102).

2. The retrievable intracranial drug-eluting stent according to claim 1, characterized in that: A plurality of main support rods (201) are arranged along the axial direction of the support body (100), and each of the main support rods (201) is a cosine wave structure.

3. The retrievable intracranial drug-eluting stent according to claim 2, characterized in that: An auxiliary support rod (202) is further provided between two adjacent main support rods (201) of the support body (100), and both ends of each auxiliary support rod (202) are respectively connected in an alternating manner to two adjacent main support rods (201).

4. The retrievable intracranial drug-eluting stent according to claim 3, characterized in that: One end of the auxiliary support rod (202) is connected to the trough portion (2013) of the cosine wave structure of the main support rod (201), and the other end is connected to the peak portion (2014) of the cosine wave structure of the adjacent main support rod (201); the outer diameter of the support body (100) forms a group of auxiliary support rods (202) along the axial direction; and the two groups of auxiliary support rods (202) adjacent to each other in the axial direction are distributed in an "eight"-shaped structure or in parallel.

5. The retrievable intracranial drug-eluting stent according to claim 4, characterized in that: The width of the auxiliary support rod (202) is smaller than the width of the main support rod (201).

6. The retrievable intracranial drug eluting stent according to claim 2, 3 or 4, characterized in that: The main support rod (201) corresponds to the first section (101) and the second section (102) of the support body (100), and is divided into a first section (2011) and a second section (2012); the first section (2011) is composed of at least one cosine wavelength unit; the second section (2012) is composed of a plurality of cosine wavelength units; the cosine structure meshes of the first section (2011) and the second section (2012) are smoothly transitionally connected; the wavelength of the cosine wave unit of the first section (2011) is greater than the wavelength of the cosine wave unit of the second section (2012); each cosine wavelength in the second section (2012) is the same; the radial supporting force of the bell-mouth structure of the first section (101) is greater than the radial supporting force of the cylindrical hollow structure of the second section (102).

7. The retrievable intracranial drug-eluting stent according to claim 1, characterized in that: The inner and outer surfaces of the stent body (100) are processed to form surfaces with a certain degree of roughness, and the rough surfaces are provided with a drug coating for resisting acute thrombosis.

8. The retrievable intracranial drug-eluting stent according to claim 2, characterized in that: A developing mark belt (105) is wound along the main support rod (201) of the support body (100), and at least one developing point is provided on the developing mark belt (105); the developing mark belt (105) is fixed to the developing mark fixing rod (104) of the first segment (101) or / and the second segment (102) by welding to form a developing point; the number of developing mark belts (105) provided on each support body (100) is at least 2, and the number of each developing mark belt (105) is consistent with the number of developing mark fixing rods (104).

9. The retrievable intracranial drug-eluting stent according to claim 1, characterized in that: The clamping portion (1032) of the recyclable connecting claw (103) can be detachably connected to the recovery groove (3021) of the recyclable connecting piece (302) of the conveying device (300).

Images